67159-82-4

Usage

Usage

Antihistamine for treating allergic conditions like hay fever and hives.

Mechanism of Action

Blocks histamine action in the body, reducing allergy symptoms.

Symptoms Treated

Sneezing, itching, watery eyes, runny nose.

Form

Available in oral medication form (tablets or syrup).

Side Effects

Generally well-tolerated when taken as directed; few side effects.

Generation

First-generation antihistamine.

Availability

Over-the-counter in many countries.

Upstream product

• 54672-48-9 4-(4-bromo-phenyl)-4-methyl-pentan-2-one 
• 108-86-1 bromobenzene 
• 541-47-9 3-Methylbutenoic acid 

Downstream Products

• 67437-33-6 Methyl-3-(p-bromphenyl)-3-methylbutanoat 
• 67159-83-5 β-(4-Brom-phenyl)-isovaleriansaeurechlorid 
• 67437-25-6 1,1-Diphenyl-3-(p-bromphenyl)-3-methyl-1-buten 
• 92846-14-5 3-(4-bromophenyl)-3-methyl-butyraldehyde 
• 67437-34-7 1,1-Diphenyl-3-(p-bromphenyl)-3-methyl-1-butanol 
• 67437-27-8 1,1-Diphenyl-3-(p-cyanophenyl)-3-methyl-1-buten 
• 67437-41-6 1,1-Diphenyl-2-(p-hydroxyphenyl)-3,3-dimethylcyclopropan 
• 67437-35-8 1,1-Diphenyl-2-(p-bromphenyl)-3,3-dimethylcyclopropan 

Relevant academic research and scientific papers

GPR35 MODULATORS

Described herein are GPR35 modulators and methods of using these compounds in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

(PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with ΤGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.

CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME

Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.